Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cost Effectiveness and Resource Allocation
Published in: Cost Effectiveness and Resource Allocation 1/2018

Open Access 01-12-2018 | Research

Cost-effectiveness of antiviral prophylaxis during pregnancy for the prevention of perinatal hepatitis B infection in South Korea

Authors: Donghoon Lee, Hyun-Young Shin, Sang Min Park

Published in: Cost Effectiveness and Resource Allocation | Issue 1/2018

Login to get access

Abstract

Background

In Korea, hepatitis B virus (HBV) infection accounts for approximately 65–75% of HBV-related diseases, such as chronic hepatitis and liver cancer, and mother-to-child transmission is presumed to be a major source of the infection. To tackle this issue, the Korean government launched the national Perinatal Hepatitis B Prevention Program (PHBPP) in 2002. This study analyzed the cost-effectiveness of the PHBPP with antiviral prophylaxis compared with the current PHBPP and/or universal vaccination, as well as identified the optimal strategy to eliminate mother-to-child transmission of HBV in Korea.

Methods

A decision tree model with the Markov process was developed and simulated over the lifetime of a birth cohort in Korea during the year 2014. The current PHBPP providing HBV vaccine and hepatitis B immune globulin to neonates born to HBV positive mothers was compared against two other strategies, universal vaccination of HBV and PHBPP with antiviral prophylaxis, with respect to their costs and health outcomes. The Korean National Health Insurance database was investigated to estimate the costs of HBV-related diseases and utilization of health resources. Costs were assessed from the health care system perspective and converted to 2014 US dollars. Health outcome measures were quality-adjusted life years (QALYs) and number of HBV-related diseases and deaths. Both costs and QALYs were discounted at 5%, following the recommendation of the Health Insurance Review & Assessment Service in Korea. The incremental cost-effectiveness ratio (ICER) obtained from the analysis was evaluated using the willingness-to-pay (WTP) in the Korean society.

Results

PHBPP with antiviral prophylaxis in Korea was cost-effective compared with the current PHBPP. An introduction of antiviral prophylaxis to pregnant women with a high viral load of HBV averted 13 HBV-related deaths per 100,000 people and saved 82 QALYs in total (ICER: $16,159/QALY).

Conclusions

Considering that WTP in Korea is $29,000, PHBPP with antiviral prophylaxis appears to be a cost-effective strategy. To further decrease the burden of perinatal hepatitis B in Korea, adding antiviral prophylaxis to PHBPP is recommended.
Appendix
Available only for authorised users
Literature
1.
McMahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology. 2009;49:S45–55.CrossRefPubMed
2.
Chae HB, Kim JH, Kim JK, Yim HJ. Current status of liver diseases in Korea: hepatitis B. Clin Mol Hepatol. 2009;15(60):13–24.
3.
Cheon JH, Park JW, Park WK, et al. The Clinical Report of 1078 cases of Hepatocellular carcinomas: National Cancer Center Experience. Clin Mol Hepatol. 2004;10(4):288–97.
4.
Kim SR, Kudo M, Hino O, Han KH, Chung YH, Lee HS. Epidemiology of Hepatocellular carcinoma in Japan and Korea. Oncology. 2008;75:13–6.CrossRefPubMed
5.
Sim JG, Seo JK, Suh SJ. Prevalence and its changes of hepatitis B viral markers from 1988 to 1993 in Korean Children. Korean J Pediatr. 1995;38(11):1535–9.
6.
Han BS, Kim IS, Suh I. A study of the seroconversion rates of anti-HBs and the duration of anti-HBs persistence after hepatitis B vaccination. Epidemiol Heal. 1989;11(2):215–31.
7.
Korea Centers for Disease Control and Prevention. Korea Health Statistics 2015 : Korea National Health and Nutrition Examination Survey (KNHANES VI-3). 2016.
8.
Choe WH, Lee JS. Preventing vertical transmission of hepatitis B virus. Korean J Intern Med. 2014;87:557–64.CrossRef
9.
Korea Centers for Disease Control and Prevention. Guideline for the Perinatal Hepatitis B Prevention Program. 2017.
10.
Kim J-H. The Appraisement of Perinatal Hepatitis B Virus Transmission Control Program in Republic of Korea. Korea Centers for Disease Control and Prevention 2011.
11.
Chen H, Lin L, Hu F, et al. Effects of maternal screening and universal immunization to prevent mother-to-infant transmission of HBV. Gastroenterology. 2012;142(4):773–81.CrossRefPubMed
12.
Brown RS, McMahon BJ, Lok ASF, et al. Antiviral therapy in chronic hepatitis B viral infection during pregnancy: a systematic review and meta-analysis. Hepatology. 2016;63(1):319–33.CrossRefPubMed
13.
Kim J-H, Choi EH, Park SE, et al. Recommended immunization schedule for children and adolescents: immunization Guideline (8th edition) released by the Korean Pediatric Society in 2015. Korean J Pediatr. 2016;59(12):461–5.CrossRefPubMedPubMedCentral
14.
World Health Organization. Hepatitis B vaccines: WHO position paper. Wkly Epidemiol Rec. 2009;84(40):405–20.
15.
Fan L, Owusu-Edusei K, Schillie SF, Murphy TV. Cost-effectiveness of active-passive prophylaxis and antiviral prophylaxis during pregnancy to prevent perinatal hepatitis B virus infection. Hepatology. 2016;63(5):1471–80.CrossRefPubMed
16.
Statistics Korea. Annual Report on Live Births and Deaths Statistics (Based on Vital Registration). 2014.
17.
Klingler C, Thoumi AI, Mrithinjayam VS. Cost-effectiveness analysis of an additional birth dose of hepatitis B vaccine to prevent perinatal transmission in a medical setting in Mozambique. Vaccine. 2012;31(1):252–9.CrossRefPubMed
18.
Sonnenberg FA, Beck JR. Markov models in medical decision making a practical guide. Med Decis Mak. 1993;13(4):322–38.CrossRef
19.
Kim S-Y, Salomon JA, Goldie SJ. Economic evaluation of hepatitis B vaccination in low-income countries: using cost-effectiveness affordability curves. Bull World Health Organ. 2007;85:833–42.CrossRefPubMedPubMedCentral
20.
Lu SQ, McGhee SM, Xie X, Cheng J, Fielding R. Economic evaluation of universal newborn hepatitis B vaccination in China. Vaccine. 2013;31(14):1864–9.CrossRefPubMed
21.
Tu HAT, de Vries R, Woerdenbag HJ, et al. Cost-effectiveness analysis of hepatitis B immunization in Vietnam: application of cost-effectiveness affordability curves in health care decision making. Value Heal Reg Issues. 2012;1(1):7–14.CrossRef
22.
Pan CQ, Duan Z, Bhamidimarri KR, et al. An algorithm for risk assessment and intervention of mother to child transmission of hepatitis B virus. Clin Gastroenterol Hepatol. 2012;10(5):452–9.CrossRefPubMed
23.
Wen W-H, Chang M-H, Zhao L-L, et al. Mother-to-infant transmission of hepatitis B virus infection: significance of maternal viral load and strategies for intervention. J Hepatol. 2013;59(1):24–30.CrossRefPubMed
24.
Zanetti AR, Dentico P, Del Vecchio Blanco C, et al. Multicenter trial on the efficacy of HBIG and vaccine in preventing perinatal hepatitis B. Final report. J Med Virol. 1986;18(4):327–34.CrossRefPubMed
25.
Chen H, Lin L, Hu F, et al. Effects of maternal screening and universal immunization to prevent mother-to-infant transmission of HBV. Gastroenterology. 2012;142(4):773–81 (e2).CrossRefPubMed
26.
Wong VW, Reesink H, Ip HH, et al. Prevention of the HBsAg carrier state in newborn infants of mothers who are chronic carriers of HBsAg and HBeAg by administration of hepatitis-B vaccine and hepatitis-B immunoglobulin: double-blind randomised placebo-controlled study. Lancet. 1984;323(8383):921–6.CrossRef
27.
Wheeley SM, Jackson PT, Boxall EH, et al. Prevention of perinatal transmission of hepatitis B virus (HB V): a comparison of two prophylactic schedules. J Med Virol. 1991;35(3):212–5.CrossRefPubMed
28.
Sehgal A, Sehgal R, Gupta I, Bhakoo ON, Ganguly NK. Use of hepatitis B vaccine alone or in combination with hepatitis B immunoglobulin for immunoprophylaxis of perinatal hepatitis B infection. J Trop Pediatr. 1992;38(5):247–51.CrossRefPubMed
29.
Edmunds WJ, Medley GF, Nokes DJ, O’Callaghan CJ, Whittle HC, Hall AJ. Epidemiological patterns of hepatitis B virus (HBV) in highly endemic areas. Epidemiol Infect. 1996;117(2):313–25.CrossRefPubMedPubMedCentral
30.
Wiseman E, Fraser MA, Holden S, et al. Perinatal transmission of hepatitis B virus: an Australian experience. Med J Aust. 2009;190(9):489.PubMed
31.
Zanetti AR, Magliano EM, Tanzi E, et al. HBIG immunoprophylaxis of babies born to HBsAg carrier mothers. Dev Biol Stand. 1982;54:383–9.
32.
Shi Z, Yang Y, Ma L, Li X, Schreiber A. Lamivudine in late pregnancy to interrupt in utero transmission of hepatitis B virus: a systematic review and meta-analysis. Obstet Gynecol. 2010;116(1):147–59.CrossRefPubMed
33.
Lee D, Shin HY, Park SM. Cost-effectiveness analysis of national Perinatal Hepatitis B Prevention Program. 2016.
34.
Korea Centers for Disease Control and Prevention. Korea Health Statistics 2014 : Korea National Health and Nutrition Examination Survey (KNHANES VI-2). 2015.
35.
Margolis HS, Coleman PJ, Brown RE, Mast EE, Sheingold SH, Arevalo JA. Prevention of hepatitis B virus transmission by immunization: an economic analysis of current recommendations. JAMA. 1995;274(15):1201–8.CrossRefPubMed
36.
Fan L, Owusu-Edusei K Jr, Schillie SF, Murphy TV. Cost-effectiveness of testing hepatitis B-positive pregnant women for hepatitis B e antigen or viral load. Obstet Gynecol. 2014;123(5):929.CrossRefPubMedPubMedCentral
37.
Edmunds WJ, Medley GF, Nokes DJ, Hall AJ, Whittle HC. The influence of age on the development of the hepatitis B carrier state. Proc R Soc Lond B. 1993;253:197-201. 
38.
Statistics Korea. Life Tables for Korea, 1970–2015. 2016.
39.
Kim Y, Shin S, Park J, et al. Costing Methods in Healthcare. National Evidence-based Healthcare Collaborating Agency. 2013.
40.
Kim J. Prevention of perinatal hepatitis B infection in high risk pregnant women through antenatal anti-viral agent. 2014.
41.
42.
Seong SC, Kim Y-Y, Khang Y-H, et al. Data resource profile: The National Health Information Database of the National Health Insurance Service in South Korea. Int J Epidemiol. 2016;41:dyw253.CrossRef
43.
Statistics Korea. Korean Statistical Information Service (KOSIS).
44.
Ock M, Lim SY, Lee H-J, Kim S-H, Jo M-W. Estimation of utility weights for major liver diseases according to disease severity in Korea. BMC Gastroenterol. 2017;17(1):103.CrossRefPubMedPubMedCentral
45.
Aggarwal R, Ghoshal UC, Naik SR. Assessment of cost-effectiveness of universal hepatitis B immunization in a low-income country with intermediate endemicity using a Markov model. J Hepatol. 2003;38(2):215–22.CrossRefPubMed
46.
47.
Wong JB, Bennett WG, Koff RS, Pauker SG. Pretreatment evaluation of chronic hepatitis c: risks, benefits, and costs. JAMA. 1998;280(24):2088–93.CrossRefPubMed
48.
Bae E-Y. Guidelines for economic evaluation of pharmaceuticals in Korea. J Prev Med Public Heal. 2008;41(2):80–3.CrossRef
49.
Bonneux L, Birnie E. The discount rate in the economic evaluation of prevention: a thought experiment. J Epidemiol Community Health. 2001;55(2):123–5.CrossRefPubMedPubMedCentral
50.
Brouwer WBF, Niessen LW, Postma MJ, Rutten FFH. Need for differential discounting of costs and health effects in cost effectiveness analyses. BMJ. 2005;331(7514):446–8.CrossRefPubMedPubMedCentral
51.
52.
Yoon J, Seo H, Oh IH, Yoon SJ. The non-communicable disease burden in Korea: findings from the 2012 Korean burden of disease study. J Korean Med Sci. 2016;31:S158–67.CrossRefPubMedPubMedCentral
53.
Hung H-F, Chen H-H. Cost-effectiveness analysis of prophylactic lamivudine use in preventing vertical transmission of hepatitis B Virus infection. Pharmacoeconomics. 2011;29(12):1063–73.CrossRefPubMed
54.
Wang W, Wang J, Dang S, Zhuang G. Cost-effectiveness of antiviral therapy during late pregnancy to prevent perinatal transmission of hepatitis B virus. PeerJ. 2016;4:e1709.CrossRefPubMedPubMedCentral
55.
Yang B-M, Kim DJ, Byun KS, Kim HS, Park J-W, Shin S. The societal burden of HBV-related disease: South Korea. Dig Dis Sci. 2010;55(3):784–93.CrossRefPubMed
56.
Statistics Korea. Annual Report on the Consumer Price Index. 2006.
57.
Statistics Korea. Annual Report on the Consumer Price Index. 2014:1–8.
58.
Sullivan SD, Mauskopf JA, Augustovski F, et al. Budget impact analysis—principles of good practice: report of the ISPOR 2012 budget impact analysis good practice II task force. Value Heal. 2014;17(1):5–14.CrossRef
Metadata
Title
Cost-effectiveness of antiviral prophylaxis during pregnancy for the prevention of perinatal hepatitis B infection in South Korea
Authors
Donghoon Lee
Hyun-Young Shin
Sang Min Park
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Cost Effectiveness and Resource Allocation / Issue 1/2018
Electronic ISSN: 1478-7547
DOI
https://doi.org/10.1186/s12962-018-0088-9

Other articles of this Issue 1/2018

Cost Effectiveness and Resource Allocation 1/2018 Go to the issue

Review

Value judgment of health interventions from different perspectives: arguments and criteria

Research

Using a dynamic adherence Markov model to assess the efficiency of Respiratory Medication Therapy Adherence Clinic (RMTAC) on asthma patients in Malaysia

Research

Cost-effectiveness analysis of secukinumab versus other biologics and apremilast in the treatment of active Psoriatic arthritis: a Finnish perspective

Research

Cost-effective interventions for breast cancer, cervical cancer, and colorectal cancer: new results from WHO-CHOICE

Research

Medical advice-seeking behaviors based on transaction cost theory

Research

Cost-effectiveness of diagnostic tests for threatened preterm labor in singleton pregnancy in France